Navigation Links
Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
Date:10/26/2011

HORSHAM, Pa., Oct. 26, 2011 /PRNewswire/ -- Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of breathing-control disorders, announced today that its board of directors has elected Thomas J. Dietz, Ph.D., as the company's chairman.  Dr. Dietz is chairman and CEO of Waypoint Holdings, LLC, a diversified financial-holdings and services company.  

Previously, Dr. Dietz was co-CEO and then CEO and a director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities.  Dr. Dietz served as head of the investment banking division at Wedbush until November 2010.  

Prior to taking the CEO role at Pacific Growth, Dr. Dietz served as the company's director of equities research and was an award-winning biotechnology and biopharmaceutical analyst.  He joined Pacific Growth in 1993.  Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center.  Dr. Dietz is a member of several national societies and currently serves on the boards of trustees of several non-profit organizations, including the West Bay Region board of the Sutter Health System that includes California Pacific Medical Center, San Francisco.  

Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.  

About Galleon Pharmaceuticals

Galleon is the first pharmaceutical company to focus primarily on the drug treatment of breathing-control disorders.  Its initial goals are to improve the safety, efficacy and economics associated with the acute care of surgical patients and longer-term care of patients with conditions such as moderate-to-severe pain or sleep apnea.  In the United States alone, it is estimated that 100 million patients are at risk for a breathing-control disorder due to drugs, diseases or genetics.

The company's product pipeline reflects recent advances in neurobiology, molecular biology and respiratory medicine which have enabled the development of a unique drug-discovery platform and promising drug candidates that are now undergoing clinical trials.  Galleon's integrated discovery and development approach is unique among pharmaceutical companies and enables the rapid evaluation of multiple variables to establish a comprehensive profile of breathing-control activity.  For more information, please visit www.galleonpharma.com.  


'/>"/>
SOURCE Galleon Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
2. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
3. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
4. Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimers Disease
5. Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
6. MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
7. Osteotechs Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council
8. PharMEDium Hires Thomas W. Rasnic as Vice President, Quality, Regulatory Affairs and Research and Development
9. Symmetry Medical Board of Directors Appoints Thomas J. Sullivan President and Chief Executive Officer
10. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
11. Thomas, McNerney & Partners Expands Team and Moves West Coast Office to San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
Breaking Medicine Technology:
(Date:10/13/2017)... TX (PRWEB) , ... October 13, 2017 , ... ... planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, is ... boy fighting to overcome a rare and deadly chromosome abnormality. , After struggling ...
(Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
Breaking Medicine News(10 mins):